制药行业产品跳跃:垄断还是创新

发布时间：2018-03-24 12:11

  本文选题：品牌制药企业　切入点：仿制药企业　出处：《科技管理研究》2017年11期

【摘要】：产品跳跃有改换形式、添加或移除某些化合物、将单独出售的两种或以上药物以组合形式重新包装等形式,常常被视为原研药企阻击竞争对手仿制药企的一种战略,从而受到反垄断的审查和规制。然而,排除那些存在制造隐患、恶意诋毁或创新骗局外,更多的产品跳跃是一种创新活动,对其严苛监管既有悖市场竞争规则,也很难权衡利弊得失,从长远角度来看还会在很大程度上抑制整个行业的发展并最终传导到消费者,降低全社会福祉。
[Abstract]:Product hopping takes the form of changing, adding or removing certain compounds, repackaging two or more drugs sold separately in combination, and so on, often seen as a strategy for the original pharmaceutical industry to block rival generic drug companies. However, excluding those who create hidden dangers, malicious slander or innovation scam, more product jumping is an innovative activity, and strict supervision of it is contrary to the rules of market competition. It is also difficult to weigh the pros and cons. In the long run, it will greatly restrain the development of the whole industry and ultimately transmit to consumers and reduce the welfare of the whole society.
【作者单位】： 台州广播电视大学;台州学院经贸管理学院;浙江天讼律师事务所;
【基金】：国家社会科学基金项目“‘战略-形象’协同视角下国家知识产权形象建设研究(13BGL003)
【分类号】：D922.294;D971.2;DD912.29
，

本文编号：1658234